PURPOSE: To determine if time to diagnosis is associated with stage of disease at diagnosis or survival among women with symptomatic ovarian cancer. METHODS: A representative sample of Australian women (n = 1,463) with ovarian cancer diagnosed between 2002 and 2005 who participated in a population-based case-control study were interviewed regarding the events leading to their diagnosis and were observed for mortality for 5 years. RESULTS: Of the 1,318 women (90%) who presented to a medical practitioner with symptoms, 55% presented within 1 month, 70% in less than 2 months, and 92% within 6 months of symptom onset. There were no significant differences in the time from symptom onset to first medical practitioner consultation (P = .19) or symptom onset to diagnosis (P = .64) among women with borderline, early (International Federation of Gynecology and Obstetrics [FIGO] stages I to II) or late (FIGO stages III to IV) disease. There was also no association between time to diagnosis and survival; adjusted hazard ratio for long delay (> 12 months from symptom onset to diagnosis) versus short delay (≤ 1 month) was 0.94 (95% CI, 0.68 to 1.30). Women who had asymptomatic cancers diagnosed incidentally (n = 145) were younger and were more likely to have borderline or stage I disease compared with women who had symptomatic ovarian cancer. CONCLUSION: The results of this study suggest that, once ovarian cancer is symptomatic, reducing the time to diagnosis would not greatly alter stage of disease at diagnosis or survival.
PURPOSE: To determine if time to diagnosis is associated with stage of disease at diagnosis or survival among women with symptomatic ovarian cancer. METHODS: A representative sample of Australian women (n = 1,463) with ovarian cancer diagnosed between 2002 and 2005 who participated in a population-based case-control study were interviewed regarding the events leading to their diagnosis and were observed for mortality for 5 years. RESULTS: Of the 1,318 women (90%) who presented to a medical practitioner with symptoms, 55% presented within 1 month, 70% in less than 2 months, and 92% within 6 months of symptom onset. There were no significant differences in the time from symptom onset to first medical practitioner consultation (P = .19) or symptom onset to diagnosis (P = .64) among women with borderline, early (International Federation of Gynecology and Obstetrics [FIGO] stages I to II) or late (FIGO stages III to IV) disease. There was also no association between time to diagnosis and survival; adjusted hazard ratio for long delay (> 12 months from symptom onset to diagnosis) versus short delay (≤ 1 month) was 0.94 (95% CI, 0.68 to 1.30). Women who had asymptomatic cancers diagnosed incidentally (n = 145) were younger and were more likely to have borderline or stage I disease compared with women who had symptomatic ovarian cancer. CONCLUSION: The results of this study suggest that, once ovarian cancer is symptomatic, reducing the time to diagnosis would not greatly alter stage of disease at diagnosis or survival.
Authors: Allison J Love; Pascal Lambert; Donna Turner; Robert Lotocki; Erin Dean; Shaundra Popowich; Alon D Altman; Mark W Nachtigal Journal: CMAJ Open Date: 2017-02-07
Authors: Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Aww Lim; D Mesher; A Gentry-Maharaj; N Balogun; M Widschwendter; I Jacobs; P Sasieni; U Menon Journal: BJOG Date: 2015-05-29 Impact factor: 6.531
Authors: James Dilley; Matthew Burnell; Aleksandra Gentry-Maharaj; Andy Ryan; Christina Neophytou; Sophia Apostolidou; Chloe Karpinskyj; Jatinderpal Kalsi; Tim Mould; Robert Woolas; Naveena Singh; Martin Widschwendter; Lesley Fallowfield; Stuart Campbell; Steven J Skates; Alistair McGuire; Mahesh Parmar; Ian Jacobs; Usha Menon Journal: Gynecol Oncol Date: 2020-06-17 Impact factor: 5.482
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Cancer Date: 2021-08-04 Impact factor: 6.860
Authors: Garth Funston; Marije Van Melle; Marie-Louise Ladegaard Baun; Henry Jensen; Charles Helsper; Jon Emery; Emma J Crosbie; Matthew Thompson; Willie Hamilton; Fiona M Walter Journal: BMC Cancer Date: 2019-11-01 Impact factor: 4.430